NCT | Title | Condition | Status | Contact |
NCT05379595 | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (NCT05379595) | Advanced or Metastatic Colorectal Cancer | RECRUITING | |
NCT04895709 | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (NCT04895709) | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | RECRUITING | |
NCT05217446 | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (NCT05217446) | Metastatic Colorectal Cancer | RECRUITING | |
NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448) | Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer | RECRUITING | |
NCT05677113 | A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver (NCT05677113) | Colorectal Cancer, Liver Metastases | RECRUITING | |
NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (NCT05253651) | Colorectal Neoplasms | RECRUITING | |
NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (NCT04449874) | Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors | RECRUITING | |
NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (NCT05538130) | Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer | RECRUITING | |
NCT04421820 | BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (NCT04421820) | Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma | RECRUITING | saali@ohri.ca; roleclerc@ohri.ca |
NCT02906943 | Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (NCT02906943) | Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gynecological Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Rare Cancer, Unknown Primary Cancer | RECRUITING | |
NCT05428735 | The DRAGON 2 Trial (NCT05428735) | Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR) | RECRUITING | |